Hannequin et al. (Hannequin et al. 2022) developed a PET/CT prognostic signature focused on tumor PD-L1 expression, but neither PET nor CT RFs in their study significantly distinguished PD-L1 status. The gene discussed is CD274; the disease is neoplasm.